Repare Therapeutics Inc. RPTX
We take great care to ensure that the data presented and summarized in this overview for Repare Therapeutics Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding RPTX
View all-
Bvf Inc San Francisco, CA10.3MShares$13.2 Million0.51% of portfolio
-
Blue Owl Capital Holdings LP New York, NY3.44MShares$4.41 Million1.93% of portfolio
-
Orbimed Advisors LLC San Diego, CA3.32MShares$4.25 Million0.12% of portfolio
-
Chi Advisors LLC New York, NY2.97MShares$3.8 Million17.66% of portfolio
-
Versant Venture Management, LLC San Francisco, CA2.65MShares$3.39 Million5.13% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl2MShares$2.56 Million0.02% of portfolio
-
Redmile Group, LLC San Francisco, CA1.92MShares$2.45 Million0.2% of portfolio
-
Mpm Asset Management LLC Cambridge, MA1.68MShares$2.16 Million1.77% of portfolio
-
Aquilo Capital Management, LLC San Francisco, CA1.29MShares$1.66 Million2.64% of portfolio
-
Bio Impact Capital LLC Cambridge, MA1.23MShares$1.58 Million0.24% of portfolio
Latest Institutional Activity in RPTX
Top Purchases
Top Sells
About RPTX
Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, which is under Phase I clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. The company was incorporated in 2016 and is headquartered in Montreal, Canada.
Insider Transactions at RPTX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 01
2024
|
Steve Forte EVP, CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
789
-1.73%
|
$3,156
$4.61 P/Share
|
|
Apr 01
2024
|
Lloyd Mitchell Segal PRESIDENT AND CEO |
SELL
Open market or private sale
|
Indirect |
2,491
-2.26%
|
$9,964
$4.63 P/Share
|
|
Apr 01
2024
|
Maria Koehler EVP, CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
300
-0.13%
|
$1,200
$4.66 P/Share
|
|
Apr 01
2024
|
Michael Zinda EVP, CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
410
-0.57%
|
$1,640
$4.66 P/Share
|
|
Mar 28
2024
|
Steve Forte EVP, CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
825
-1.78%
|
$3,300
$4.62 P/Share
|
|
Mar 28
2024
|
Lloyd Mitchell Segal PRESIDENT AND CEO |
SELL
Open market or private sale
|
Indirect |
2,650
-2.35%
|
$10,600
$4.62 P/Share
|
|
Mar 28
2024
|
Maria Koehler EVP, CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
500
-0.22%
|
$2,000
$4.64 P/Share
|
|
Mar 28
2024
|
Michael Zinda EVP, CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
450
-0.62%
|
$1,800
$4.64 P/Share
|
|
Mar 27
2024
|
Lloyd Mitchell Segal PRESIDENT AND CEO |
SELL
Open market or private sale
|
Indirect |
2,650
-3.06%
|
$10,600
$4.63 P/Share
|
|
Mar 27
2024
|
Maria Koehler EVP, CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
500
-0.21%
|
$2,000
$4.62 P/Share
|
|
Mar 27
2024
|
Michael Zinda EVP, CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
450
-0.61%
|
$1,800
$4.62 P/Share
|
|
Mar 27
2024
|
Steve Forte EVP, CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
825
-1.92%
|
$3,300
$4.62 P/Share
|
|
Mar 26
2024
|
Lloyd Mitchell Segal PRESIDENT AND CEO |
SELL
Open market or private sale
|
Indirect |
2,650
-2.97%
|
$10,600
$4.64 P/Share
|
|
Mar 26
2024
|
Maria Koehler EVP, CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
500
-0.21%
|
$2,000
$4.6 P/Share
|
|
Mar 26
2024
|
Michael Zinda EVP, CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
450
-0.61%
|
$1,800
$4.61 P/Share
|
|
Mar 26
2024
|
Steve Forte EVP, CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
825
-1.88%
|
$3,300
$4.6 P/Share
|
|
Mar 25
2024
|
Lloyd Mitchell Segal PRESIDENT AND CEO |
SELL
Open market or private sale
|
Indirect |
2,650
-2.89%
|
$10,600
$4.79 P/Share
|
|
Mar 25
2024
|
Maria Koehler EVP, CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
500
-0.21%
|
$2,000
$4.78 P/Share
|
|
Mar 25
2024
|
Michael Zinda EVP, CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
450
-0.61%
|
$1,800
$4.78 P/Share
|
|
Mar 25
2024
|
Steve Forte EVP, CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
825
-1.85%
|
$3,300
$4.79 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 82K shares |
|---|
| Open market or private sale | 21.7K shares |
|---|